Drug Developer City Therapeutics Files for US IPO

Why it matters

New biotech IPO adds to healthcare issuance pipeline but single-firm filing has minimal market signal.

Related assets & topics

Sources

• googlenews · news.google.com · 2026-09-24 20:52 UTC
• googlenews · news.google.com · 2026-09-24 20:57 UTC
• googlenews · news.google.com · 2026-09-24 20:57 UTC
• googlenews · news.google.com · 2026-09-24 20:47 UTC

Related stories

• Global Nanomedicine Market to Reach USD 581.2 Bn. by 2034, Driven by Rising Chronic Disease Prevalence, Expanding Nanotechnology-Based Drug Delivery, and Advances in Precision Diagnostics and Therapeutics Says Maximize Market Research
  News · 2026-09-24 22:30 UTC
• Global Autoimmune Treatment Market to Reach USD 321.95 Billion by 2034, Driven by Rising Prevalence of Autoimmune Diseases, Growing Adoption of Biologics, and Advances in Precision Medicine Says Maximize Market Research
  News · 2026-09-24 22:15 UTC
• Global Placenta Market to Reach USD 275.18 Billion by 2034, Driven by Rising Demand for Placenta-Based Cosmetics, Pharmaceuticals and Dietary Supplements Says Maximize Market Research
  News · 2026-09-24 22:00 UTC
• Global Bioinformatics Market to Reach USD 64.60 Billion by 2034, Driven by AI, Genomics, Next-Generation Sequencing, and Precision Medicine Report Maximize Market Research
  News · 2026-09-24 21:45 UTC
• CTY IPO News - RNA interference biotech City Therapeutics files for a $100 million IPO
  News · 2026-09-24 21:38 UTC

More on the feed →